iCST Web-application for People With Dementia

November 18, 2020 updated by: University of Nottingham

Adapting Individual Cognitive Stimulation Therapy (iCST) for Delivery by a Web-application

In the UK, over 670,000 older people are living with dementia which has a substantial, multi-level impact on society, the person with dementia, and their carers. There is a need for an increase in the availability of psychological therapies since people with dementia can face difficulties with staying mentally stimulated and engaged. Cognitive Stimulation Therapy (CST) offers a person based approach and can help to relieve some of these problems. It is a brief manualised evidence based psychological treatment for people with mild to moderate dementia which has shown to improve cognition and quality of life. CST is currently available in both a group and individualised format called iCST. It is worthwhile to explore a computerised version of iCST since it would take together the added value of computer use and the beneficial effects of iCST which might produce combined, positive effects on cognition and quality of life. The investigators have spoken to people with dementia and their carers who are keen on using technology to stay mentally active and stimulated. This study sets out to develop and evaluate the potential benefits of an iCST web-application within a feasibility study. The effects on cognition and quality of life between (a) usual care and (b) iCST web-application over 11 weeks will be compared. A web-application is a website which can easily be accessed on and is compatible with computers and tablets. In order to create the most appropriate and practical web-application, the research team will work closely together with people with dementia, their carers, and the software company. An iCST web-application will compliment traditional CST by making it even more accessible since technology users will be able to access it easily on their device. Furthermore, a computerised version of iCST will by highly relevant for upcoming generations who have grown up with the use of technology.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Scientific justification:

Since the use of technology is rapidly increasing in every aspect of many people's daily lives, previous research has already begun to investigate its application and implementation in multiple areas within dementia care. An example of an area where technology and dementia come together is computerised cognitive interventions. These types of interventions build on the added benefits of computer use such as reduced cognitive decline in older adults and lower risk of receiving a diagnosis of dementia among older men with the added benefits of using one's cognitive capacities. In a recent systematic review, Garcia-Casal et al. (2016) concluded that computerised cognitive interventions led to significant improvements in cognition, depression and anxiety among people with dementia. Computerised cognitive interventions may have more of an impact on cognition than non-computerised cognitive interventions.

In a randomised pilot trial conducted by Tárraga et al. (2006) which was included in Garcia-Casal's review, people with mild Alzheimer's Disease were allocated to a treatment group and a control group. The treatment group consisted of both a computerised cognitive stimulation programme and a non-computerised, face-to-face cognitive stimulation programme delivered in groups. The control group consisted solely of the non-computerised, cognitive stimulation programme. The results showed that that people with mild Alzheimer's Disease showed greater improvements in cognition lasting for 24 weeks in the treatment group which suggests added benefits of a computerised cognitive stimulation programme.

These positive findings suggest that it is worthwhile to continue conducting research in the area of computerised cognitive interventions. Interestingly, Garcia-Casal et al (2016) have pointed out that the area of computerised cognitive stimulation (which is an area of computerised cognitive interventions) is relatively underdeveloped. Most computerised cognitive interventions are geared towards cognitive training.

At the moment there are multiple, paper-based cognitive stimulation interventions available of which Cognitive Stimulation Therapy is being used more predominantly in the UK. CST is a brief evidence-based psychological treatment for people with mild to moderate dementia. It consists of mentally stimulating and engaging group activities which have shown to improve cognition and quality of life in a large scale randomised controlled trial. More recently, an individualised version of CST (iCST) was developed which is a home-based version of CST administered by informal carers (e.g., friends, family members). The content of the sessions is similar to those of CST. A multi-centre RCT of iCST showed no improvements in cognition and QoL for people with dementia, nor evidence of improvements in carers' mental and physical health. However, people with dementia receiving iCST reported a better relationship quality with their carer, and carers reported an improved health-related QoL. These findings indicate a need for further research to determine the effectiveness of carer-led cognitive stimulation interventions for people with dementia since most people received fewer than recommended number of iCST due to low adherence.

Since there is a need for more research in both the area of computerised cognitive stimulation and carer-led cognitive stimulation, this research sets out to develop and evaluate the potential benefits of iCST adapted for delivery by an interactive (touch-screen) web-application in a feasibility study. The investigators are setting out to combine the added value of computer use and the beneficial effects of CST/iCST in order to produce benefits in cognition and quality of life. A participatory process while developing the web-application in the form of consultations, focus groups and interviews will be employed. Preliminary consultations with people with dementia and their carers have already given the investigators information on attitudes towards (touch-screen) technology, both appealing and non-appealing features of applications and desired length/duration of iCST.

The investigators hope to see signs of improvements in quality of life and cognition after using the iCST web-application. If this is the case, this could lead to a larger randomised controlled trial with more participants to formally establish effectiveness. An iCST web-application has the potential to be more accessible for people on a national and an international level when adapted to appropriate cultural contexts compared to paper-based manuals. Lastly, the iCST web-application could be used long-term and could rapidly become widely used as a clinically and cost-effective standardised, and feasible intervention.

Design and methodology:

  1. The focus groups and interviews will be a multi-centre study to gain insights and perspectives from people with dementia and their carers regarding the usability of the iCST web-app. This will enable the investigators to optimise the developmental process and learn about the experiences of the participants while they interact with the web-application. Observational and transcribed audio-recorded data will be collected from the focus groups and interviews which will be semi-structured in nature.
  2. The feasibility study will be a multicentre, pragmatic, single blind, randomised 2 treatment arm (iCST web-app vs treatment as usual) study over 11 weeks.

In accordance with good research practice, the investigators have decided to run a feasibility study prior to running a larger randomised controlled trial in order to assess the usability of the iCST web-application and the feasibility of running a larger-scale randomised clinical trial. With this feasibility study the investigators will be able to gain insights with regard to recruitment/drop-out rates, adherence, sample size, appropriateness of outcome measures, changes to made to the web-application etc. This will all be necessary information before a larger trial can be conducted.

Programme development:

The iCST web-application will be adapted from the paper-based iCST manual. The amount of sessions will be reduced from 75 to 21 after consultations with people with dementia and carers pointed out that the paper-based iCST manual contained too many sessions. Multimedia within the web-application will be used and participants will be given the opportunity to provide ongoing feedback on the web-application itself after completing each session. The research team will work together with all the stakeholders such as the software company employed to build the web-application, the people with dementia, and their carers. Regular consultations, focus groups and interviews should aid the development of the web-application in ensuring it is feasible, practical and appealing.

Recruitment for the study:

Recruitment for the focus groups, interviews and feasibility study will take place in a variety of community settings in Nottingham consisting of both primary care settings (outpatient clinics) and secondary care settings (community mental health teams (CMHTs), memory clinics, care homes, day centres, and voluntary sector organizations such as the Alzheimer's Society). By including a variety of settings, the reach for people with dementia and their carers will be extended. The PhD student will make close links with the aforementioned services and organisations through attendance and regular contact. In addition, the distribution of information leaflets and posters to organisations and professionals involved in the identification of possible participants will facilitate the recruitment process.

The initial approach will be from a member of the person with dementia's usual care team. If the person with dementia and carer are willing and suitable for participation, the PhD student will fully inform them about of all aspects pertaining to involvement in the study through in person conversations and information leaflets. It will be explained to the potential participant that; (i) entry into the study is entirely voluntary and that their treatment and care will not be affected by their decision, (ii) they can withdraw at any time but attempts will be made to avoid this occurrence and (iii) in the event of their withdrawal their data collected so far cannot be erased and we will seek consent to use the data in the final analyses where appropriate.

Sample size:

The sample size estimation for the focus groups and interviews is based on previous work in the iCST study. For the current study, four focus groups with six participants each (one with people with dementia, one with carers, two collaborative groups) and ten interviews (five with people with dementia and five with carers) will be conducted.

The investigators have estimated the sample size to be 60 participants. This is partly based on previous work with iCST considering the numbers recruited and the amount of centres involved in the iCST trial. The iCST trial recruited 356 participants over eight sites across the UK (Bangor, Devon, Dorset, Hull, Lincolnshire, London, Manchester, Norfolk and Suffolk). This equals to an average of 45 dyads per site. We will have an equal distribution of dyads across the two groups leading to 30 dyads per arm (iCST web-application vs. treatment-as-usual). The field-testing phase of iCST (without a control group) included 22 dyads which roughly resembles the sample size for the current feasibility study.

A sample size of 60 participants will be sufficient to demonstrate the effectiveness of the iCST web-application with an effect size of 0.80 with 80% power and 5% significance (two-tailed). The effect size has been chosen based on the sample size.

Timetable:

Focus groups/interviews (start from May 2018 onwards):

  1. 3 months recruitment;
  2. 4 months running of groups and interviews in Nottingham recruitment
  3. 6 months analysis and writing up findings

Feasibility trial (start from November 2018 onwards):

  1. 5 months of recruitment;
  2. 7 months of running feasibility study;
  3. 5 months analysis and writing up findings

Study Type

Interventional

Enrollment (Actual)

43

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United Kingdom
    • Derbyshire
      • Derby, Derbyshire, United Kingdom, DE22 3LZ
        • Derbyshire healthcare NHS foundation trust
    • Leicestershire
      • Leicester, Leicestershire, United Kingdom, LE2 2PL
        • Leicestershire Partnership NHS Trust
    • Lincolnshire
      • Lincoln, Lincolnshire, United Kingdom, LN1 1EJ
        • Lincolnshire partnership NHS foundation trust
    • Nottinghamshire
      • Nottingham, Nottinghamshire, United Kingdom, NG7 2TU
        • Nottinghamshire Healthcare Nhs Trust

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

Person with dementia:

  • Meet Diagnostic and Statistical Manual of Mental Disorders (DSM IV) criteria for dementia (American Psychiatric Association, 2013).
  • Score 10 or above on the Mini Mental State Examination (MMSE) (Folstein, Folstein, & McHugh, 1975) or score of 16 or above on the Montreal Cognitive Assessment (MoCA) (Trzepacz et al., 2015) where available.
  • Some ability to communicate and understand (e.g. ability to give informed consent)
  • Ability to speak and understand English
  • See/hear well enough to participate
  • No major physical illness or disability affecting their participation
  • Age range: 50 years - no maximum age limit
  • Availability of a tablet to the person with dementia and carer
  • Availability of a carer (or friend/befriender) to participate in the focus groups, interviews and iCST web-app sessions

Carer:

  • Minimum age: 21
  • Ability to speak and understand English
  • See/hear well enough to participate
  • No major physical illness or disability affecting their participation

Exclusion criteria

Person with dementia and carer:

- Concurrent participation in any other interventional study for people with dementia/carers

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: iCST web-application
A computerised cognitive stimulation programme consisting of 21 sessions.
Behavioral: iCST web-application
The iCST web-application will be delivered by a carer in regular contact with the person with dementia (family carer, a close friend, or a volunteer befriender) for 1.5 hours a week. It is up to the carer to distribute the time in a matter that is convenient to them (e.g. two long sessions of 45 minutes or 3 shorter sessions of 30 minutes). Participants will be asked to use the web-application for a duration of 11 weeks at their homes. Each session will consist of structured cognitive stimulation aided by the use of multimedia. After completing each session, participants will be guided to a new screen on the web-application in which they will be asked to briefly reflect on the session and provide us with feedback.
No Intervention: Treatment as usual (TAU)
The control group will consist of a treatment-as-usual group and will not receive any additional intervention.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in cognition (person with dementia)
Time Frame: Pre-intervention (baseline), 5 weeks post baseline, 11 weeks post baseline
ADAS-Cog: to measure the severity of the cognitive symptoms (memory, language, praxis, attention and other cognitive abilities)
Pre-intervention (baseline), 5 weeks post baseline, 11 weeks post baseline
Change in quality of life (person with dementia)
Time Frame: Pre-intervention (baseline), 5 weeks post baseline, 11 weeks post baseline
QoL-AD: self reporting questionnaire to investigate: physical health, energy, mood, living situation, memory, marriage, friends, chores, fun, money, self and life).
Pre-intervention (baseline), 5 weeks post baseline, 11 weeks post baseline
Change in general health outcome (carer)
Time Frame: Pre-intervention (baseline), 5 weeks post baseline, 11 weeks post baseline
EQ-5D: An instrument used to measure health outcome, it provides a descriptive profile for health status. It evaluates quality of life in carers.
Pre-intervention (baseline), 5 weeks post baseline, 11 weeks post baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Depression (person with dementia)
Time Frame: Pre-intervention (baseline), 5 weeks post baseline, 11 weeks post baseline
CSDD: to measure depressive symptoms: mood-related signs, behavioural disturbances, physical signs, biological functions and ideational disturbances
Pre-intervention (baseline), 5 weeks post baseline, 11 weeks post baseline
Behavioural symptoms (person with dementia)
Time Frame: Pre-intervention (baseline), 5 weeks post baseline, 11 weeks post baseline
NPI: to asses 10 behavioural disturbances: delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy and aberrant motor activity.
Pre-intervention (baseline), 5 weeks post baseline, 11 weeks post baseline
Activities of daily living (person with dementia)
Time Frame: Pre-intervention (baseline), 5 weeks post baseline, 11 weeks post baseline
BADLS: BADLS is an instrument consisting of 20 daily-living abilities (basic and instrumental activities)
Pre-intervention (baseline), 5 weeks post baseline, 11 weeks post baseline
Relation between person with dementia and carer (both)
Time Frame: Pre-intervention (baseline), 5 weeks post baseline, 11 weeks post baseline
QPCR: a measure of relationship quality which will be completed by both the person with dementia and the carer
Pre-intervention (baseline), 5 weeks post baseline, 11 weeks post baseline
Depression/anxiety (carer)
Time Frame: Pre-intervention (baseline), 5 weeks post baseline, 11 weeks post baseline
HADS: is a useful measure anxiety and depression for carer. It consists of 14 questions (7 for anxiety and 7 for depression).
Pre-intervention (baseline), 5 weeks post baseline, 11 weeks post baseline

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Computer use self efficacy
Time Frame: Pre-intervention (baseline)
CUSE: will be used to assess self-efficacy beliefs in the context of computer/tablet use
Pre-intervention (baseline)
System usability
Time Frame: 11 weeks post baseline
SUS: is a widely-used questionnaire measuring the usability of a technology-based tool e.g. a computer program or other device.
11 weeks post baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Nottingham

Investigators

  • Study Chair: Martin Orrell, MD, PhD, University of Nottingham
  • Study Director: Justine Schneider, PhD, University of Nottingham
  • Principal Investigator: Harleen Rai, MSc., University of Nottingham
  • Study Director: Lauren Yates, PhD, University of Nottingham

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2018

Primary Completion (Actual)

June 30, 2020

Study Completion (Actual)

June 30, 2020

Study Registration Dates

First Submitted

July 19, 2017

First Submitted That Met QC Criteria

September 13, 2017

First Posted (Actual)

September 14, 2017

Study Record Updates

Last Update Posted (Actual)

November 19, 2020

Last Update Submitted That Met QC Criteria

November 18, 2020

Last Verified

November 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • iCST web-application

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Mild Dementia

Clinical Trials on iCST web-application

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe